MarketCap
Facebook
X
Telegram
Onconova Therapeutics Income Statement 2025-2010 | ONTX
Brief overview of income trends at Onconova Therapeutics
The conclusions below are based on five years of reported results. Revenue reported by Onconova Therapeutics was $231 thousand at the beginning of the period and $2.8 million at the end. The total change was +1107.8%, with a CAGR of approximately 64.6%. Sales grew at a rate typical of a strong expansion phase.
EBITDA changed from −25 million dollars to −17.8 million dollars (+28.7%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was −10813.9% at the start and −638.5% at the end. The business generated more EBITDA from each unit of revenue.
Across the five years, the net result shifted from −25.2 million dollars to 9.2 million dollars. The return to profit marks a meaningful recovery in the final result.
Financial takeaway
The figures do not all move in the same direction. The constructive conclusion rests on an improving EBITDA margin, a larger revenue base and a stronger final result. The overall view is constrained by limited operating profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Onconova Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 1.55 M | 840 K | 15.3 M | 42.9 M | 117 M | 5.18 M | 10.1 M | 12.9 M | 11.2 M | 14.3 M | 83.4 M | 161 M | - | - | - |
Shares |
8.23 M | 1.55 M | 840 K | 20.9 M | 16.8 M | 11.6 M | 959 K | 275 K | 40 K | 19.7 K | 10.1 K | 9.62 K | 4.71 K | - | - | - |
Historical Prices |
- | 1 | 1 | 0.73 | 2.55 | 7.05 | 5.7 | 31.6 | 338 | 511 | 2.16 K | 7.4 K | 25.8 K | - | - | - |
Net Income |
9.17 M | -167 M | -18.9 M | -19 M | -16.2 M | -25.2 M | -21.5 M | -20.6 M | -24.1 M | -19.7 M | -24 M | -63.7 M | -62.5 M | -29.9 M | -26.3 M | - |
Revenue |
2.79 M | 226 K | 226 K | 226 K | 226 K | 231 K | 2.18 M | 1.23 M | 787 K | 5.55 M | 11.5 M | 800 K | 4.75 M | 46.2 M | 1.49 M | - |
Gross Profit |
- | - | - | - | - | 231 K | - | - | - | - | - | 800 K | 4.75 M | 46.2 M | - | - |
Operating Income |
-17.9 M | -142 M | -20.3 M | -19.6 M | -16.5 M | -25 M | -21.7 M | -23.3 M | -25.7 M | -23.7 M | -24 M | -63.7 M | -62.2 M | -22.3 M | -27.6 M | - |
Interest Expense |
478 K | 289 K | 1.35 M | 663 K | 12 K | 48 K | 143 K | 1.15 M | 30 K | 62 K | -35 K | 2 K | 4 K | 8.61 M | 19 K | - |
EBITDA |
-17.8 M | -142 M | -20.3 M | -19.6 M | -16.5 M | -25 M | -21.7 M | -23.2 M | -25.6 M | -23.6 M | -23.8 M | -63.3 M | -61.8 M | -22 M | -27.3 M | - |
Operating Expenses |
20.7 M | 143 M | 20.5 M | 19.9 M | 16.7 M | 25.2 M | 23.9 M | 24.5 M | 26.5 M | 29.2 M | 35.4 M | 64.5 M | 67 M | 68.5 M | - | - |
General and Administrative Expenses |
8.52 M | 12.3 M | 9.09 M | 8.45 M | 9.42 M | 8.33 M | 8.34 M | 7.59 M | 7.4 M | 9.18 M | 9.53 M | 15.1 M | 16.8 M | - | 6.44 M | - |
All numbers in USD currency
Quarterly Income Statement Onconova Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
10.6 M | 8.82 M | 5.82 M | 6.97 M | 3.65 M | 962 K | 1.01 M | 842 K | 840 K | 840 K | 21 M | 21 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 16 M | 15.8 M | 14.6 M | 12.4 M | 12.1 M | 11.6 M | 160 M | 111 M | 6.14 M | 5.95 M | 5.89 M | 5.67 M | 5.67 M | 4.07 M | 1.01 M | 718 K | 657 K | 9 M | 6.77 M | 6.76 M | 5.44 M | 2.74 M | 2.73 M | 2.55 M | 2.26 M | 2.17 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 21.6 M | 21.4 M | 15.5 M | 2.61 M | 2.61 M | 2.31 M | 2.17 M | 2.17 M | 2.17 M | - | - | - | - |
Net Income |
-7.11 M | -3.96 M | -915 K | 21.5 M | - | -8.48 M | -123 M | -4.98 M | - | -4.74 M | -4.25 M | -5.78 M | - | -5.4 M | -4.02 M | -4.12 M | - | -3.45 M | -4.23 M | -4.72 M | - | -6.24 M | -7.4 M | -5.09 M | - | -4.6 M | -3.56 M | -7.6 M | - | -5.35 M | -4.48 M | -5.09 M | - | -6.96 M | -2.58 M | -8.34 M | - | -1.6 M | -5.38 M | -7.24 M | - | -5.87 M | -8.96 M | -12.3 M | -13.4 M | -14.9 M | -16.8 M | -18.7 M | -14.6 M | -20.5 M | -12.6 M | -14.8 M | -10.3 M | -1.44 M | -7.42 M | -10.8 M | - | - | - | - |
Revenue |
57 K | - | 2.73 M | 57 K | - | 57 K | 57 K | 56 K | - | 57 K | 57 K | 56 K | - | 57 K | 57 K | 56 K | - | 57 K | 57 K | 56 K | - | 66 K | 56 K | 52 K | - | 63 K | 2.02 M | 68 K | - | 120 K | 485 K | 564 K | - | 110 K | 324 K | 210 K | - | 1.65 M | 2.25 M | 1.47 M | - | 1.62 M | 123 K | 114 K | 114 K | 114 K | 125 K | 447 K | 1.93 M | 1.12 M | 591 K | 1.12 M | 2.97 M | 42.8 M | 220 K | 198 K | - | - | - | - |
Operating Income |
-6.95 M | -4.06 M | -1.25 M | -5.2 M | - | -8.54 M | -123 M | -5.21 M | - | -5.09 M | -4.61 M | -6.14 M | - | -5.64 M | -4.12 M | -4.13 M | - | -3.99 M | -4.64 M | -4.1 M | - | -6.27 M | -7.34 M | -5.12 M | - | -5.1 M | -3.63 M | -7.24 M | - | -5.59 M | -5.64 M | -5.9 M | - | -6.76 M | -6.07 M | -6.79 M | - | -4.32 M | -5.4 M | -7.52 M | - | -5.88 M | -8.96 M | -12.3 M | -13.4 M | -14.9 M | -16.8 M | -18.7 M | -14.6 M | -20.1 M | -12.6 M | -15 M | -10.3 M | 6.92 M | -8.18 M | -10.7 M | - | - | - | - |
Interest Expense |
-2 K | 96 K | 188 K | 180 K | - | 61 K | 205 K | 229 K | - | 350 K | 360 K | 362 K | - | 243 K | 96 K | 10 K | - | 7 K | -13 K | 19 K | - | -23 K | 96 K | 96 K | - | 27 K | 40 K | 68 K | - | 117 K | 112 K | - | - | 8 K | 11 K | - | - | 10 K | 10 K | 9 K | - | 4 K | -18 K | -18 K | -14 K | -20 K | -19 K | 1 K | 1 K | 1 K | 2 K | 127 K | 41 K | 8.36 M | 230 K | 21 K | - | - | - | - |
EBITDA |
-6.9 M | -4.04 M | - | -5.2 M | - | - | - | -5.21 M | - | - | - | -6.13 M | - | -5.63 M | -4.11 M | -4.13 M | - | -3.98 M | -4.64 M | -4.1 M | - | -6.26 M | -7.33 M | -5.12 M | - | -5.09 M | -3.62 M | -7.23 M | - | -5.55 M | -5.61 M | -5.89 M | - | -6.69 M | -6.02 M | -6.77 M | - | -4.24 M | -5.35 M | -7.5 M | - | -5.75 M | -8.86 M | -12.3 M | -13.4 M | -14.6 M | -16.5 M | -18.6 M | -14.6 M | -19.8 M | -12.4 M | -14.9 M | -10.3 M | 7.15 M | -8.03 M | -10.7 M | - | - | - | - |
Operating Expenses |
6.95 M | 4.06 M | 3.98 M | 5.26 M | - | 8.59 M | 123 M | 5.27 M | - | 5.15 M | 4.67 M | 6.19 M | - | 5.7 M | 4.18 M | 4.19 M | - | 4.05 M | 4.7 M | 4.15 M | - | 6.34 M | 7.4 M | 5.18 M | - | 5.16 M | 5.66 M | 7.31 M | - | 5.71 M | 6.12 M | 6.47 M | - | 6.87 M | 6.39 M | 7 M | - | 5.97 M | 7.65 M | 8.99 M | - | 7.5 M | 9.08 M | 12.5 M | 13.5 M | 15 M | 16.9 M | 19.2 M | 16.5 M | 21.2 M | 13.2 M | 16.1 M | 13.3 M | 35.9 M | 8.4 M | 10.9 M | - | - | - | - |
General and Administrative Expenses |
2.03 M | 1.74 M | 1.69 M | 2.75 M | - | 3.48 M | 1.98 M | 3.36 M | - | 2.69 M | 2.21 M | 2.11 M | - | 2.1 M | 2.14 M | 2.19 M | - | 2.28 M | 2.85 M | 2.22 M | - | 2.15 M | 2.59 M | 1.81 M | - | 1.64 M | 1.76 M | 3.23 M | - | 1.73 M | 2.05 M | 1.89 M | - | 1.73 M | 1.78 M | 2.12 M | - | 1.98 M | 2.08 M | 3.17 M | - | 2.22 M | 2.57 M | 2.96 M | 3.09 M | 3.12 M | 3.98 M | 4.93 M | 4.4 M | 5.93 M | 3.12 M | 3.35 M | 2.7 M | 8.92 M | 1.63 M | 2.46 M | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Onconova Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
